Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 21;27(5):947–952. doi: 10.1093/annonc/mdw044

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press on behalf of the European Society for Medical Oncology 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

PMC Copyright notice

Figure 3. — Peripheral blood mononucleocyte histone acetylation relationship to panobinostat dose and plasma concentration, response, toxicity, and white cell count. Histone acetylation neither correlates with panobinostat dose (A) nor plasma concentration (ng/ml, B). (C) Box plots of histone acetylation in patients who did (CB) versus those who did not (PD) benefit from treatment and in patients who experienced grade 1/2 versus grade 3/4 toxicity. (D) Dot plots of all leukocytes (WBC), neutrophils (ANC), and lymphocytes (Lympho) on day 5 of treatment normalized to pretreatment on day 1 of cycle 1 comparing patients who did (CB) and did not (PD) benefit from treatment. The bar indicates the mean. Correlations were conducted using Pearson's correlation coefficient method.